Verition Fund Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Verition Fund Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-80,094	Closed	-$5.45M	–	3238
2022 Q3	$5.45M	Buy	+80,094	New	+$4.42M	0.06%	377
2021 Q4	–	Sell	-41,989	Closed	-$1.07M	–	2951
2021 Q3	$1.07M	Buy	+41,989	New	+$1.23M	0.01%	895
2020 Q4	–	Sell	-4,270	Closed	-$235K	–	1472
2020 Q3	$235K	Buy	4,270 +1,007	+31%	+$64K	﹤0.01%	878
2020 Q2	$206K	Buy	+3,263	New	+$224K	0.01%	943
2018 Q2	–	Sell	-4,351	Closed	-$210K	–	1411
2018 Q1	$210K	Buy	+4,351	New	+$243K	0.02%	996

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Verition Fund Management's GBT Position: Q4 2022 in Review

Verition Fund Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 80,094 shares — an estimated $5.45M sold.

Verition Fund Management first reported a position in GBT in Q1 2018 and held it in 5 quarters. The position peaked at $5.45M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Verition Fund Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Verition Fund Management sold 80,094 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $5.45M.
Verition Fund Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
Verition Fund Management's Global Blood Therapeutics, Inc. position peaked at $5.45M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.